Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 65

1.

Cancer: Escape from inhibition.

Courtneidge SA.

Nature. 2003 Apr 24;422(6934):827-8. No abstract available.

PMID:
12712187
[PubMed - indexed for MEDLINE]
2.

Cancer research. Why some leukemia cells resist STI-571.

Marx J.

Science. 2001 Jun 22;292(5525):2231-3. No abstract available.

PMID:
11423629
[PubMed - indexed for MEDLINE]
3.

c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).

Nagar B.

J Nutr. 2007 Jun;137(6 Suppl 1):1518S-1523S; discussion 1548S.

PMID:
17513418
[PubMed - indexed for MEDLINE]
Free Article
4.

Structural basis for the autoinhibition of c-Abl tyrosine kinase.

Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J.

Cell. 2003 Mar 21;112(6):859-71.

PMID:
12654251
[PubMed - indexed for MEDLINE]
5.

Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival.

Buschbeck M, Hofbauer S, Di Croce L, Keri G, Ullrich A.

EMBO Rep. 2005 Jan;6(1):63-9.

PMID:
15608616
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.

Nicolini FE, Chabane K, Cayuela JM, Rousselot P, Thomas X, Hayette S.

Haematologica. 2006 Jan;91(1):137-8.

PMID:
16434384
[PubMed - indexed for MEDLINE]
Free Article
7.

Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.

Cheng WH, von Kobbe C, Opresko PL, Fields KM, Ren J, Kufe D, Bohr VA.

Mol Cell Biol. 2003 Sep;23(18):6385-95.

PMID:
12944467
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.

Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, Botta M.

ChemMedChem. 2009 Jan;4(1):118-26. doi: 10.1002/cmdc.200800320.

PMID:
19039816
[PubMed - indexed for MEDLINE]
9.

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.

Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, Kuriyan J.

Mol Cell. 2006 Mar 17;21(6):787-98.

PMID:
16543148
[PubMed - indexed for MEDLINE]
Free Article
10.

Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.

Fujita A, Shishido T, Yuan Y, Inamoto E, Narumiya S, Watanabe N.

Mol Pharmacol. 2009 Jan;75(1):75-84. doi: 10.1124/mol.108.051706. Epub 2008 Oct 3.

PMID:
18835981
[PubMed - indexed for MEDLINE]
Free Article
11.

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Ren R.

Nat Rev Cancer. 2005 Mar;5(3):172-83. Review.

PMID:
15719031
[PubMed - indexed for MEDLINE]
12.

Last findings on dual inhibitors of abl and SRC tyrosine-kinases.

Schenone S, Manetti F, Botta M.

Mini Rev Med Chem. 2007 Feb;7(2):191-201. Review.

PMID:
17305593
[PubMed - indexed for MEDLINE]
13.

c-Abl regulation: a tail of two lipids.

Van Etten RA.

Curr Biol. 2003 Aug 5;13(15):R608-10. Review.

PMID:
12906815
[PubMed - indexed for MEDLINE]
14.

Gleevec target Abl important for normal immune activation of T cells.

[No authors listed]

Cancer Biol Ther. 2004 Aug;3(8):704. No abstract available.

PMID:
15751157
[PubMed - indexed for MEDLINE]
Free Article
15.

Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV.

Yi CR, Rosenberg N.

J Virol. 2008 Jun;82(11):5307-15. doi: 10.1128/JVI.00089-08. Epub 2008 Mar 26.

PMID:
18367522
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.

Cancer Res. 2005 Oct 1;65(19):8912-9.

PMID:
16204063
[PubMed - indexed for MEDLINE]
Free Article
17.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
[PubMed - indexed for MEDLINE]
18.

Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on "A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients" by Curvo et al. [Leuk. Res.].

Cho EH, Kang SK, Kim SY.

Leuk Res. 2009 Mar;33(3):505-6. doi: 10.1016/j.leukres.2008.08.024. Epub 2008 Oct 9. No abstract available.

PMID:
18848355
[PubMed - indexed for MEDLINE]
19.

Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.

Liu H, Li H, Feng Z, Tai J, Meng Y, Wang H, Xin H, Zhang S, Zuo M, Zhang Y, Chen X.

Leuk Lymphoma. 2009 Mar;50(3):437-46. doi: 10.1080/10428190802709438.

PMID:
19347730
[PubMed - indexed for MEDLINE]
20.

A novel tyrosine kinase-independent function of Drosophila abl correlates with proper subcellular localization.

Henkemeyer M, West SR, Gertler FB, Hoffmann FM.

Cell. 1990 Nov 30;63(5):949-60. No abstract available.

PMID:
2175256
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk